ID   WM3211
AC   CVCL_6797
SY   WM-3211; WM 3211; WC00045; EST79
DR   cancercelllines; CVCL_6797
DR   Coriell; WC00045
DR   Cosmic; 972286
DR   Cosmic; 1047655
DR   Cosmic; 1155289
DR   Cosmic; 1155541
DR   Cosmic; 1284919
DR   Cosmic; 1303071
DR   Cosmic; 2144978
DR   Cosmic; 2159443
DR   Cosmic; 2163806
DR   DepMap; ACH-002508
DR   ESTDAB; ESTDAB-079
DR   GEO; GSM109036
DR   GEO; GSM156008
DR   GEO; GSM185194
DR   GEO; GSM185195
DR   GEO; GSM188070
DR   GEO; GSM188122
DR   GEO; GSM188195
DR   GEO; GSM188210
DR   GEO; GSM188216
DR   GEO; GSM188233
DR   GEO; GSM188263
DR   GEO; GSM188286
DR   GEO; GSM188295
DR   GEO; GSM188322
DR   IARC_TP53; 26082
DR   Progenetix; CVCL_6797
DR   Rockland; WM3211-01-0001
DR   Wikidata; Q54994241
RX   PubMed=15592718;
RX   PubMed=16827748;
RX   PubMed=17260012;
RX   PubMed=18632627;
RX   PubMed=22578220;
RX   PubMed=23851445;
RX   PubMed=24576830;
WW   Info; Wistar; -; https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Wistar Institute melanoma cell line collection.
CC   HLA typing: A*03:01,24:02; B*07:02; C*07:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01:01,15:01 (PubMed=15592718).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; None_reported; -; Zygosity=- (Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Gln50Ter (c.148C>T); ClinVar=VCV000220711; Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:6342; KIT; Simple; p.Leu576Pro (c.1727T>C); ClinVar=VCV000375919; Zygosity=Unspecified (PubMed=23851445; PubMed=24576830; Wistar).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Cys242Gly (c.724T>G); ClinVar=VCV000376581; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; Array-based CGH.
CC   Discontinued: Coriell; WC00045; probable.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ESTDAB=ESTDAB-079; Wistar
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 29,31.2
ST   D2S1338: 20,24
ST   D3S1358: 15,16
ST   D5S818: 11
ST   D7S820: 10,12
ST   D8S1179: 10,11
ST   FGA: 20
ST   TH01: 6,9.3
ST   TPOX: 11
ST   vWA: 14,17
DI   NCIt; C4022; Acral lentiginous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   34Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 35
//
RX   PubMed=22578220; DOI=10.1111/j.1755-148X.2012.01016.x;
RA   Furney, Simon J.
RA   Turajlic, Samra
RA   Fenwick, Kerry
RA   Lambros, Maryou B.
RA   Mackay, Alan
RA   Ricken, Gerda
RA   Mitsopoulos, Costas
RA   Kozarewa, Iwanka
RA   Hakas, Jarle
RA   Zvelebil, Marketa
RA   Lord, Christopher J.
RA   Ashworth, Alan
RA   Reis-Filho, Jorge Sergio
RA   Herlyn, Meenhard
RA   Murata, Hiroshi
RA   Marais, Richard
RT   "Genomic characterisation of acral melanoma cell lines.";
RL   Pigment Cell Melanoma Res. 25:488-492(2012).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235; PMCID=PMC2615688;
RA   Smalley, Keiran S.M.
RA   Contractor, Rooha
RA   Nguyen, Thiennga K.
RA   Xiao, Min
RA   Edwards, Robin
RA   Muthusamy, Viswanathan
RA   King, Alastair J.
RA   Flaherty, Keith Thomas
RA   Bosenberg, Marcus W.
RA   Herlyn, Meenhard
RA   Nathanson, Katherine L.
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x;
RA   Hoek, Keith S.
RA   Schlegel, Natalie C.
RA   Brafford, Patricia
RA   Sucker, Antje
RA   Ugurel, Selma
RA   Kumar, Rajiv
RA   Weber, Barbara L.
RA   Nathanson, Katherine L.
RA   Phillips, Donald J.
RA   Herlyn, Meenhard
RA   Schadendorf, Dirk
RA   Dummer, Reinhard
RT   "Metastatic potential of melanomas defined by specific gene expression
RT   profiles with no BRAF signature.";
RL   Pigment Cell Res. 19:290-302(2006).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5; PMCID=PMC11032966;
RA   Rodriguez, Teresa
RA   Mendez, Rosa
RA   Roberts, Chrissy H.
RA   Ruiz-Cabello Osuna, Francisco
RA   Dodi, I. Anthony
RA   Lopez-Nevot, Miguel Angel
RA   Paco, Laura
RA   Maleno, Isabel
RA   Marsh, Steven G.E.
RA   Pawelec, Graham
RA   Garrido, Federico
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042;
RA   Nissan, Moriah Heller
RA   Pratilas, Christine A.
RA   Jones, Alexis M.
RA   Ramirez, Ricardo
RA   Won, Helen
RA   Liu, Cai-Lian
RA   Tiwari, Shakuntala
RA   Kong, Li
RA   Hanrahan, Aphrothiti J.
RA   Yao, Zhan
RA   Merghoub, Taha
RA   Ribas, Antoni
RA   Chapman, Paul B.
RA   Yaeger, Rona D.
RA   Taylor, Barry Stephen
RA   Schultz, Nikolaus
RA   Berger, Michael F.
RA   Rosen, Neal
RA   Solit, David B.
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson, Goran
RA   Dahl, Christina
RA   Staaf, Johan
RA   Sandberg, Troy
RA   Bendahl, Par-Ola
RA   Ringner, Markus
RA   Guldberg, Per
RA   Borg, Ake
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl, Christina
RA   Christensen, Claus
RA   Jonsson, Goran
RA   Lorentzen, Anders
RA   Skjodt, Mette Louise
RA   Borg, Ake
RA   Pawelec, Graham
RA   Guldberg, Per
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//